Last reviewed · How we verify
Chlorpheniramine maleate syrup
Chlorpheniramine maleate blocks histamine H1 receptors to reduce allergic symptoms and itching.
Chlorpheniramine maleate blocks histamine H1 receptors to reduce allergic symptoms and itching. Used for Allergic rhinitis, Urticaria and pruritus, Allergic reactions.
At a glance
| Generic name | Chlorpheniramine maleate syrup |
|---|---|
| Also known as | ChlorTrimeton Syrup |
| Sponsor | Organon and Co |
| Drug class | H1 receptor antagonist (first-generation antihistamine) |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | Phase 3 |
Mechanism of action
Chlorpheniramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors on various tissues, preventing histamine-mediated allergic responses. This reduces symptoms such as urticaria, pruritus, rhinitis, and other allergic manifestations. As a first-generation agent, it crosses the blood-brain barrier and commonly causes sedation.
Approved indications
- Allergic rhinitis
- Urticaria and pruritus
- Allergic reactions
Common side effects
- Drowsiness/sedation
- Dry mouth
- Dizziness
- Headache
- Anticholinergic effects (urinary retention, constipation)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlorpheniramine maleate syrup CI brief — competitive landscape report
- Chlorpheniramine maleate syrup updates RSS · CI watch RSS
- Organon and Co portfolio CI